Mar 16, 2026 4:30 pm EDT iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
Mar 9, 2026 7:00 am EDT iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss
Feb 10, 2026 4:05 pm EST iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update